A new study by Dr Thompson with colleagues Dr Alex Blazevski, Prof Phillip Stricker and others has just been published in leading journal European Urology Oncology in July 2020.
https://euoncology.europeanurology.com/current#/article/S2588-9311(19)30057-4/fulltext
The study analysed outcomes in terms of cancer cure rates and quality of life 1 year after nano-knife focal ablation therapy (also known as Irreversible Electroporation IRE therapy).
This study is a world-first due to the fact that all men underwent both MRI and trans-perineal saturation biopsy before treatment and again 1-year after treatment.
We reported excellent outcomes with almost 100% pads-free continence, >90% with good maintenance of sexual function and ~ 90% free from a significant cancer that required further treatment.
This study adds to the weight of evidence demonstrating that focal nanoknife therapy appears safe and achieves excellent outcomes in carefully selected men. It must be cautioned that not all men have cancers suitable for focal therapy (in fact the majority do NOT) and these are short term outcomes, so longer term data with 10 years + followup is required before we can be sure whether focal nanoknife therapy is a good treatment for early prostate cancer.